Aker BioMarine Collaborate with Université de Sherbrooke Department of Medicine for Alzheimer's Disease
Shots:
- The alliance will investigate the effectiveness of LPC-bound EPA/DHA in preventing cognitive decline linked to AD. Aker BioMarine will supply the research team with its krill-based LPC EPA/DHA product (Lysoveta)
- The team will evaluate the link between genetic variations in lipid metabolism & transport of EPA/DHA across the BBB using knock-in mice for human E4 (hAPOE4) or E3 (hAPOE3) genetic variants
- Aker BioMarine launches Lysoveta based on LPC-bound EPA/DHA from krill and is effective in increasing the concentration of DHA in the brain and improving cognition. The company plans to launch a product for human health in 2022
Ref: Aker BioMarine | Image: Aker BioMarine
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com